<DOC>
	<DOCNO>NCT01196403</DOCNO>
	<brief_summary>RATIONALE : Minimal-access surgery use small open body remove tumor use standard surgery . It yet know whether minimal-access surgery remove bladder effective standard surgery remove bladder treat patient bladder cancer . PURPOSE : This randomized phase II trial study standard surgery see well work compare minimal-access surgery treat patient bladder cancer .</brief_summary>
	<brief_title>Standard Surgery Minimal-Access Surgery Treating Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine feasibility randomize patient bladder cancer undergo open cystectomy versus minimal-access cystectomy ( laparoscopic robotic cystectomy ) . Secondary - To assess safety efficacy laparoscopic robotic cystectomy reason non-acceptance randomization . - To collect safety toxicity data , include measure postoperative morbidity surgical complication . ( Exploratory ) - To investigate anatomical lymph node dissection ( indicator oncological clearance ) completeness cancer surgery . ( Exploratory ) - To determine quality life patient use EORTC QLQ-C30 EORTC QLQ-BLM30 questionnaire . ( Exploratory ) OUTLINE : This multicenter study . Patients consent interview-only ( randomization ) undergo qualitative interview explore factor relate decision . Patients consent randomization randomize 1 2 treatment arm . - Arm I : Patients undergo open radical cystectomy . - Arm II : Patients undergo minimal-access radical cystectomy ( laparoscopic robotic ) . Patients complete quality-of-life questionnaire ( EORTC QLQ-C30 EORTC QLQ-BLM30 ) baseline 4 week , 6 week , 8 week , 3 month , 6 month completion study therapy . Blood , urine , tissue sample collect patient baseline study laboratory analysis . After completion study treatment , patient follow 6 week , 3 month , 6 month . Peer Reviewed Funded Endorsed Cancer Research UK . PROJECTED ACCRUAL : A total 92 patient ( 72 patient randomize portion 20 interview-only portion ) accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm bladder cancer , include follow cell type : Urothelial cell ( transitional cell ) carcinoma Squamous cell carcinoma Adenocarcinoma Stage pT1 , pT2 , pT3 disease OR mobile bladder mass bimanual examination anesthesia No enlarged node distant metastasis CT MRI scan abdomen pelvis No upper urinary tract disease PATIENT CHARACTERISTICS : American Society Anesthesiologist ( ASA ) status 13 Life expectancy &gt; 24 month Not pregnant nursing Negative pregnancy test No concurrent disease would render patient unsuitable trial No presence urosepsis PRIOR CONCURRENT THERAPY : May receive prior neoadjuvant chemotherapy provide study surgery perform 3 10 week date completion chemotherapy treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>squamous cell carcinoma bladder</keyword>
	<keyword>adenocarcinoma bladder</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
</DOC>